J
Jason R. Westin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 325
Citations - 11931
Jason R. Westin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Diffuse large B-cell lymphoma. The author has an hindex of 35, co-authored 253 publications receiving 7540 citations. Previous affiliations of Jason R. Westin include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster,Michael R. Bishop,Constantine S. Tam,Edmund K. Waller,Peter Borchmann,Joseph P. McGuirk,Ulrich Jäger,Samantha Jaglowski,Charalambos Andreadis,Jason R. Westin,Isabelle Fleury,Veronika Bachanova,S. Ronan Foley,P. Joy Ho,Stephan Mielke,Stephan Mielke,John M. Magenau,Harald Holte,Serafino Pantano,Lida Bubuteishvili Pacaud,Rakesh Awasthi,Jufen Chu,Özlem Anak,Gilles Salles,Richard T. Maziarz +24 more
TL;DR: The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.
Journal ArticleDOI
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu,Sudhakar Tummala,Partow Kebriaei,William G. Wierda,Cristina Gutierrez,Frederick L. Locke,Krishna V. Komanduri,Yi Lin,Nitin Jain,Naval Daver,Jason R. Westin,Alison M. Gulbis,Monica Loghin,John de Groot,Sherry Adkins,Suzanne E. Davis,Katayoun Rezvani,Patrick Hwu,Elizabeth J. Shpall +18 more
TL;DR: The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided.
Journal ArticleDOI
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump,Sattva S. Neelapu,Umar Farooq,Eric Van Den Neste,John Kuruvilla,Jason R. Westin,Brian K. Link,Annette E. Hay,James R. Cerhan,Liting Zhu,Sami Boussetta,Lei Feng,Matthew J. Maurer,Lynn Navale,Jeff Wiezorek,William Y. Go,Christian Gisselbrecht +16 more
TL;DR: SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL, the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients withRefractoryDLBCL.
Journal ArticleDOI
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin,Fuliang Chu,Min Zhang,Luis Fayad,Larry W. Kwak,Nathan Fowler,Jorge E. Romaguera,Fredrick B. Hagemeister,Michelle A. Fanale,Felipe Samaniego,Lei Feng,Veerabhadran Baladandayuthapani,Zhiqiang Wang,Wencai Ma,Yanli Gao,Michael J. Wallace,Luis M Vence,Laszlo Radvanyi,Tariq Muzzafar,Rinat Rotem-Yehudar,R. Eric Davis,Sattva S. Neelapu +21 more
TL;DR: The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4, and the results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.
Journal ArticleDOI
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil,Michael D. Jain,Lei Feng,Jay Y. Spiegel,Armin Ghobadi,Yi Lin,Saurabh Dahiya,Matthew A. Lunning,Lazaros J. Lekakis,Patrick M. Reagan,Olalekan O. Oluwole,Joseph P. McGuirk,Abhinav Deol,Alison R. Sehgal,Andre Goy,Brian T. Hill,Khoan Vu,Charalambos Andreadis,Javier Munoz,Jason R. Westin,Julio C. Chavez,Amanda F. Cashen,N. Nora Bennani,Aaron P. Rapoport,Julie M. Vose,David B. Miklos,Sattva S. Neelapu,Frederick L. Locke +27 more
TL;DR: The safety and efficacy of axi-cel in the standard-of-care (SOC) setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.